Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor

Trial Profile

Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ORCHIDEE
  • Most Recent Events

    • 28 Nov 2016 Status changed from recruiting to discontinued.
    • 15 Dec 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 22 Jul 2015 Planned initiation date changed from 1 Feb 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top